Integrated NGS testing and cfDNA analysis as an approach for aggregate tumor characterization and monitoring in a patient with aggressive lymphoma invading the central neural system.

NAVRKALOVÁ, Veronika, Andrea MAREČKOVÁ, Jakub Paweł PORC, Marie JAROŠOVÁ, Šárka POSPÍŠILOVÁ, Jana KOTAŠKOVÁ and Andrea JANÍKOVÁ. Integrated NGS testing and cfDNA analysis as an approach for aggregate tumor characterization and monitoring in a patient with aggressive lymphoma invading the central neural system. In EHA-SWG Scientific Meeting Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease, Francie, Bordeaux. 2022.

Basic information

• Original name: Integrated NGS testing and cfDNA analysis as an approach for aggregate tumor characterization and monitoring in a patient with aggressive lymphoma invading the central neural system.
• Authors: NAVRKALOVÁ, Veronika, Andrea MAREČKOVÁ, Jakub Paweł PORC, Marie JAROŠOVÁ, Šárka POSPÍŠILOVÁ, Jana KOTAŠKOVÁ and Andrea JANÍKOVÁ.
• Edition: EHA-SWG Scientific Meeting Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease, Francie, Bordeaux, 2022.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• NU22-08-00227, research and development project: Name: Pokročilé molekulární analýzy pro komplexní diagnostiku a monitorování pacientů s difúzním velkobuněčným B-lymfomem: využití profilování genové exprese, tekutých biopsií a sekvenování třetí generace

Investor: Ministry of Health of the CR, Advanced molecular testing for aggregate diagnosis and management of DLBCL patients: engagement of gene expression profiling, liquid biopsy and long-read sequencing, Subprogram 1 - standard

• NV19-03-00091, research and development project: Name: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby

Investor: Ministry of Health of the CR